Tecentriq-Avastin Combo Leads to ‘Longest Survival’ in Liver Cancer

Tecentriq-Avastin Combo Leads to ‘Longest Survival’ in Liver Cancer

283501

Tecentriq-Avastin Combo Leads to ‘Longest Survival’ in Liver Cancer

First-line therapy with a combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) significantly prolongs the survival of people with inoperable hepatocellular carcinoma (HCC) — the most common form of liver cancer — according to updated data from an ongoing Phase 3 trial. The latest findings from the study, called IMbrave150 (NCT03434379), showed that the combination therapy lowered the risk of death by 34% compared with Nexavar (sorafenib), a current standard of care. “These results show that…

You must be logged in to read/download the full post.